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Abstract
Currently, autologous chondrocyte transplantation (ACT) is
used to treat traumatic cartilage damage or osteochondrosis
dissecans, but not degenerative arthritis. Since substantial
refinements in the isolation, expansion and transplantation of
chondrocytes have been made in recent years, the treatment of
early stage osteoarthritic lesions using ACT might now be
feasible. In this study, we determined the gene expression
patterns of osteoarthritic (OA) chondrocytes ex vivo after
primary culture and subculture and compared these with healthy
chondrocytes ex vivo and with articular chondrocytes expanded
for treatment of patients by ACT. Gene expression profiles were
determined using quantitative RT-PCR for type I, II and X
collagen, aggrecan, IL-1β and activin-like kinase-1. Furthermore,
we tested the capability of osteoarthritic chondrocytes to
generate hyaline-like cartilage by implanting chondrocyte-
seeded collagen scaffolds into immunodeficient (SCID) mice.
OA chondrocytes ex vivo showed highly elevated levels of IL-1β
mRNA, but type I and II collagen levels were comparable to
those of healthy chondrocytes. After primary culture, IL-1β levels
decreased to baseline levels, while the type II and type I collagen
mRNA levels matched those found in chondrocytes used for
ACT. OA chondrocytes generated type II collagen and
proteoglycan-rich cartilage transplants in SCID mice. We
conclude that after expansion under suitable conditions, the
cartilage of OA patients contains cells that are not significantly
different from those from healthy donors prepared for ACT. OA
chondrocytes are also capable of producing a cartilage-like
tissue in the in vivo SCID mouse model. Thus, such
chondrocytes seem to fulfil the prerequisites for use in ACT
treatment.
Introduction
Hyaline articular cartilage is a tissue designed for weight bear-
ing, shock absorption and providing the gliding surfaces
needed for movement of joints. Since the self-renewal and
repair capabilities of cartilage are very limited [1], even small
injuries to articular cartilage can cause degeneration that
eventually requires surgical management at later stages of car-
tilage destruction [2]. Current surgical treatments include tis-
sue response techniques (for example, Pridie drilling,
microfracturing), osteochondral transplantation and ultimately
the implantation of artificial joints.
An additional treatment, the autologous chondrocyte trans-
plantation (ACT) technique, was introduced more than a dec-
ade ago [3,4]. This technique is based on the isolation of
chondrocytes from a small piece of knee cartilage taken from
a non-load-bearing area, followed by in vitro expansion of
these cells and their re-implantation into the defect area [5].
Guidelines of medical societies based on clinical experience
ACT = autologous chondrocyte transplantation; ALK = activin-like kinase; ALP = alkaline phosphatase; DMEM = Dulbecco's modified Eagle's 
medium; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; IL = interleukin; OA = osteoarthritis; PBS = phosphate buffered saline; qRT-PCR 
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suggest that larger defects (≥4 cm2) should be treated using
the ACT method [6]. Since patients diagnosed with degener-
ative arthritis generally have larger cartilage defects in the
patellofemoral contact area, ACT would be the preferred treat-
ment for the regeneration of such large defects. While current
International Cartilage Repair Society (ICRS) criteria do not
recommend ACT as a therapeutic option for elderly patients or
patients suffering from degenerative, reactive or inflammatory
arthritis, a recent study using ACT to treat patients suffering
from early degenerative arthritis indicates that this method
might indeed be a therapeutic option for osteoarthritic lesions
[7]. One major question remaining is whether osteoarthritic
chondrocytes are changed irreversibly or, upon expansion
under optimized conditions, are comparable with those cells
that are currently used for ACT and are able to generate hya-
line cartilage.
Molecular strategies for monitoring the gene expression pat-
terns of chondrocytes destined for ACT were developed
recently for the quality management of therapeutic cell culture
and the safety of ACT patients [8,9]. To evaluate whether fun-
damental differences exist between osteoarthritic chondro-
cytes and cells currently used for the ACT procedure, we
employed these quality management regimens and compared
the expression of key factors for cartilage regeneration, includ-
ing type I and II collagens, aggrecan, IL-1β and activin-like
kinase (ALK)-1. We compared chondrocytes from osteoarthri-
tis (OA) patients to chondrocytes from healthy donors directly
after cell harvest (ex vivo) and to those from patients undergo-
ing ACT after primary in vitro expansion (P0 cells) and first
subculture (P1 cells). ALK-1 is a receptor involved in TGF-β
signalling [10] and is proposed to be a marker for irreversible
chondrocyte dedifferentiation [11]. The OA chondrocytes
were prepared and expanded under the same good manufac-
turing practice protocols applied for ACT, except that autolo-
gous serum was not available from OA patients due to the
regulations imposed by the local ethics committee. Therefore,
clinical grade human AB serum was used instead of autolo-
gous serum for the in vitro culture of chondrocytes.
To determine whether OA chondrocytes were still capable of
in vivo cartilage formation, we implantated collagen scaffolds
seeded with these chondrocytes ectopically into severe com-
bined immune deficient (SCID) mice. The formation of type II
collagen and proteoglycan-rich hyaline cartilage-like tissue
could be shown using histochemistry and immunohistochemi-
cal staining of implant sections.
We report that OA chondrocytes generated a proteoglycan
and type II collagen-rich cartilaginous tissue when seeded
onto a collagen scaffold at higher densities. We conclude that
OA chondrocytes might be able to regenerate cartilage when
applied under suitable conditions.
Materials and methods
Donors
Chondrocytes from OA patients were obtained from macro-
scopically intact cartilage areas of 29 patients undergoing
knee joint implant surgery. Samples were taken from the inter-
condylar femoral notch (fossa intercondylica). The average
age of the OA patients at the time of surgery was 67.2 ± 10.1
years (minimum 46 years, maximum 89 years). To compare the
status of these cells with cells that are actually used for ACT,
chondrocytes obtained from human articular cartilage biopsies
from the femoral notch of 41 patients undergoing ACT were
included in this study. All procedures followed the guidelines
for ACT to treat chondral defects [6]. ACT surgery was per-
formed as described previously [3]. The average age of the
patients at the time of ACT was 32.3 ± 10.0 years (minimum
16 years, maximum 57 years).
Since all the chondrocytes from the ACT patients had to be
used for expansion and transplantation, no ACT cells were
available for analysis ex vivo. As a surrogate for ACT ex vivo
controls, chondrocytes were obtained from the cartilage of six
knee joints of individuals without any osteoarthritic symptoms
(36.6 ± 12.5 years, minimum 23 years, maximum 50 years)
either post mortem (n = 1) or after amputation (n = 5). The
study was approved by the local ethics committee.
Chondrocyte isolation and in vitro expansion
Cartilage samples, excluding the mineralized cartilage and the
subchondral bone, were washed twice in PBS (BioWhittaker,
Verviers, Belgium) and then minced. Extracellular matrix was
enzymatically degraded overnight by incubation in DMEM/
Ham's F12 medium (BioWhittaker; Verviers, Belgium) contain-
ing 2.5 mg/ml type II collagenase (Roche, Mannheim, Ger-
many) and 5% serum at 37°C. Cell culture medium for ACT
chondrocytes was supplemented with autologous serum, cul-
ture medium for OA chondrocytes with human AB serum. Iso-
lated chondrocytes were resuspended by pipetting up and
down several times and then filtered through a 100 μm mesh
to remove undigested cartilage fragments and extracellular
matrix debris. After centrifugation, the cells were resuspended
in DMEM/Ham's F12 cell culture medium supplemented with
either 10% autologous or AB serum and plated in cell culture
flasks (BD Falcon, Heidelberg, Germany) at an initial density of
1,500 cells/cm2. At this point, some of the cells were har-
vested to provide ex vivo cells.
Chondrocytes were cultured at 37°C in humidified atmos-
phere containing 5% CO2. The cells were harvested after 10
to 12 days of expansion by trypsin-EDTA (BioWhittaker) treat-
ment. Cell yields and viability were monitored by trypan blue
staining using a Neubauer hematocytometer. At this time, cells
were removed to determine gene expression patterns after pri-
mary expansion (P0), used for in vivo experiments, or cultured
for an additional 12 to 14 days to provide first subculture (P1)
cells. All procedures were performed according to the goodAvailable online http://arthritis-research.com/content/9/3/R60
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manufacturing practice guidelines required for tissue
engineering.
Gene expression analysis
RNA was extracted and isolated from chondrocytes using the
RNeasy mini kit according to the manufacturer's instructions
(Qiagen Inc., Valencia, CA, USA). To isolate RNA from the
cell-seeded scaffolds that were implanted into SCID mice, the
scaffolds were frozen in 350 μl RLT buffer (Qiagen RNeasy
Mini kit) supplemented with 10 μl/ml β-mercaptoethanol. Scaf-
folds were then homogenized using a micropestle (Eppendorf,
Hamburg, Germany) and samples were frozen at -80°C until
further isolation.
Complementary DNA (cDNA) was obtained by reverse tran-
scription of 1 μg total RNA using oligo-dT primers and MuMLV
reverse transcriptase (BD Clontech, Heidelberg, Germany).
Reverse transcription was performed in a total volume of 20 μl
at 42°C for 1 h in a thermocycler (Whatman Biometra, Göttin-
gen, Germany). Expression of mRNA/cDNA levels was deter-
mined by quantitative real-time RT-PCR (qRT-PCR;
LightCycler®, Roche) using specific target primers (Table 1)
and FastStart DNA SybrGreen reagents (Roche) according to
the protocols provided. The amplification of cDNA was per-
formed in 35 PCR cycles: after 5 initial cycles (95°C 10 s,
68°C 10 s, 72°C 16 s, temperature transition rate 20°C/s) the
annealing temperature was dropped in consecutive cycles to
60°C with a step size of 0.5°C.
To monitor the specificity of the amplification, melting curve
analysis was performed after each PCR. In addition, some
samples were separated by electrophoresis and visualized on
agarose gels to confirm the size and purity of the PCR prod-
ucts. Amplification of glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) encoding cDNA and serial dilutions of a
recombinant standard with a known DNA concentration
(Roche) served as controls in each PCR. Data show the mean
of the mRNA expression levels of the gene investigated nor-
malized by the respective GAPDH signal and recombinant
standard in each individual sample and PCR reaction. To show
the relative copy numbers of the different genes investigated
(ranging from more than 106 to less than 1 copy/μl cDNA)
Table 1
PCR primer sequences
Gene product Sequences Accession number Position Product (base-pairs)
Collagen I(a2) Up: 5'-CTGGTCCTTCTGGTCCTGTTG NM_000089 3,413
Low: 5'-GTGCGAGCTGGGTTCTTTCTA 3,957 544
Collagen II(a1) Up: 5'-CTGGCTCCCAACACTGCCAACGTC NM_033150 4,070
Low: 5'-TCCTTTGGGTTTGCAACGGATTGT 4,483 413
Collagen X Up: 5'-ACCCAAGAGGTGCCCCTGGAATAC NM_000493.2 1,416
Low: 5'-CCTGAGAAAGAGGAGTGGACATAC 2,117 701
Aggrecan Up:5'-AGCTGGGTTCGGGGCATCT NM_013227 6,039
Low:5'-TGGTAGTCTTGGGCATTGTTGTTGA 6,839 800
IL-1β Up:5'-ATGGCAGAAGTACCTAAGCTCGC NM_000576 87
Low:5'-ACACAAATTGCATGGTGAAGTCAGTT 889 802
ALK-1 Up: 5'-CGGCTCCCTCTACGACTTTCT Z_22533 1,128
Low: 5'-CAGCACTCCCGCATCATCT 1,479 570
GAPDH Up: 5'-TGAAGGTCGGAGTCAACGGATTTGGT NM_002046 113
Low: 5'-CATGTGGGCCATGAGGTCCACCAC 1,095 983
ALK = activin-like kinase; GAPDH = glyceraldehyde-3-phosphate dehydrogenase.Arthritis Research & Therapy    Vol 9 No 3    Stoop et al.
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qRT-PCR data are shown on a log scale. This required an
adjustment of all normalized values by a factor of 100,000.
Statistical evaluation of the data was performed by a Mann-
Whitney U test. Groups were considered statistically different
when the probability values p were equal to or smaller than
0.05.
In vivo cartilage formation
To investigate the capability of OA chondrocytes to form car-
tilage under in vivo conditions, primary culture cells (P0 cells)
from three osteoarthritic donors (OA donor 1, age 78 years;
OA donor 2, age 68 years; OA donor 3, 50 years) and two
healthy donors (healthy donor 1, age 50 years; healthy donor
2, age 42 years) were harvested by mild enzymatic detach-
ment, washed, counted, resuspended in cell culture medium
and seeded onto a biphasic collagen matrix (Jotec AG,
Hechingen, Germany). The scaffold consisted of a bovine col-
lagen membrane on one side and a porous collagen sponge
on the other side. The sponge side of the scaffold was seeded
with 1 × 106 or 3 × 106 OA chondrocytes/cm2 or 1 × 106
healthy chondrocytes/cm2.
The cell-scaffold constructs were then cultured in vitro for an
additional 4 days, after which they were implanted subcutane-
ously into female CB-17/Lcr SCID mice aged 10 to 12 weeks
(Charles-River Wiga, Sulzfeld, Germany; n = 3 per group). The
mice were anesthetized using ketamine and xylazine (1 ml
10% ketamine (WDT eG, Garbsen, Germany) and 1 ml xyla-
zine (Rompun®, WDT eG) in sterile PBS; 0.1 ml/10 g body
weight subcutaneously). Two scaffolds were implanted subcu-
taneously at the back of each mouse through a small incision
in the neck region. Empty scaffolds were used as controls. The
mice were kept in isolator cages in an air-conditioned specific
pathogen free facility on an unrestricted diet. After 8 weeks the
mice were sacrificed using CO2, and the constructs were har-
vested and fixed in 10% formalin buffered with 0.1 M phos-
phate buffer (pH 7.4). All procedures were approved by the
local animal care committee.
In an additional experiment, scaffolds seeded with cells from
four OA patients or three ACT patients were implanted into the
mice and harvested after eight weeks for mRNA isolation.
Histological analysis
After fixation, the constructs were embedded in Tissue Tec
compound (Sakura, Zoeterwoude, The Netherlands) and 7 μm
sections were cut with a cryomicrotome (Jung/Leica Instru-
ments, Nussloch, Germany). To determine if synthesis of car-
tilage-like tissue had occurred, we stained sections with
safranin O/fast green to show the presence of proteoglycans.
Type I and type II collagen was also visualized using standard
immunohistochemistry. Type I collagen was detected using
the 1-855 monoclonal antibody (IgG2a, ICN Pharmaceuticals,
Aurora, OH, USA), type II collagen using the II-II6B3 mono-
clonal antibody (IgG1, kappa light chain) [12] followed by a
biotin-labeled horse anti-mouse serum (Vector, Burlingame,
CA, USA). A biotin-streptavidin detection system (Vectastain
Elite Kit, Vector) was used according to the manufacturer's
recommendations. The II-II6B3 antibody was obtained from
the Developmental Studies Hybridoma Bank maintained by
the Department of Pharmacology and Molecular Sciences,
Johns Hopkins University School of Medicine, Baltimore, MD,
and the Department of Biological Sciences, University of Iowa,
Iowa City, IA, under contract NO1-HD-2-3144 from the
NICHD.
Hypertrophic chondrocytes were detected by staining for alka-
line phosphatase (ALP). Sections were washed in ALP buffer
(0.1 M Tris-HCl, 0.1 M NaCl, 5 mM MgCl2, pH 9.0) and then
incubated with 3.5 μl 5-bromo-4-chloro-3-indolyl phosphate
(50 mg/ml, Sigma Aldrich, Taufkirchen, Germany) and 4.5 μl
nitroblue tetrazolium (50 mg/ml, Sigma-Aldrich) per ml ALP
buffer. The reaction was stopped by washing with PBS.
Results
Analysis of gene expression patterns in chondrocytes ex 
vivo
In the first set of measurements, gene expression patterns
were investigated in cells directly after isolation from cartilage.
As all of the chondrocytes obtained from the ACT patients
were needed for expansion and subsequent transplantation,
ex vivo ACT chondrocytes were not available for experimental
investigation. Instead, cells from healthy cartilage served as
surrogates. Ex vivo chondrocytes from healthy donors showed
a prominent type II collagen signal by qRT-PCR and a some-
what weaker mRNA expression than OA chondrocytes (Figure
1). Type I collagen encoding mRNA was expressed to a lesser
extent, resulting in very low type I to type II collagen ratios in
both groups. The expression of aggrecan mRNA was high in
both chondrocyte populations ex vivo. In ex vivo OA chondro-
cytes it exceeded the mRNA amounts found in chondrocytes
from healthy donors (Figure 1), indicating that cells from both
groups were in a highly differentiated state. This was con-
firmed by the low expression of ALK-1, a marker for chondro-
cyte dedifferentiation, in both groups (Figure 1). However,
despite having similar collagen and aggrecan expression pat-
terns, significant differences in IL-1β mRNA levels could be
seen between healthy and OA cells: in OA chondrocytes, ex
vivo IL-1β levels were more than 8,000 times (p < 0.05) higher
than in the healthy controls (Figure 1).
Analysis of gene expression patterns in OA and ACT 
chondrocytes after primary culture
Interestingly, the high IL-1β expression observed ex vivo in OA
chondrocytes dropped strongly (1,448-fold) after 10 to 12
days of in vitro culture to expression levels only slightly higher
than the IL-1β expression of healthy chondrocytes ex vivo or of
ACT chondrocytes after primary culture. Although the increase
in type I collagen and the decrease in aggrecan expression lev-
els during culture suggested a slight dedifferentiation of theAvailable online http://arthritis-research.com/content/9/3/R60
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OA chondrocytes, culture of the OA chondrocytes also
resulted in a four-fold increase in type II collagen expression
compared to the ex vivo values (Figure 2). These levels were
almost nine times higher than those in ACT cells cultured
using the same protocol. Since the type I collagen expression
levels differed only slightly between OA and ACT chondro-
cytes (Figure 2), this led to a significantly better type I/type II
collagen ratio in OA chondrocytes than in the OA cells. Com-
bined with the slightly lower ALK-1 expression in the OA cells,
this suggests that the phenotypic state of OA chondrocytes is
at least comparable to, if not better than, that of ACT cells at
the stage where the latter are used for transplantation back
into the patient.
Gene expression in OA chondrocytes after in vitro 
expansion
Since defect sizes in OA cartilage are expected to be larger
than those currently treated using the ACT method, the
number of cells required for ATC will be greater as well.
Therefore, we further expanded the OA chondrocytes and
analyzed the gene expression patterns in first subculture cells
(P1). We found that the expression of type II collagen mRNA
was much weaker (23-fold; Figure 3) in P1 OA chondrocytes
than in P0 cells. Although the expression of type I collagen
remained constant, this still led to a 270-fold increase of the
type I to type II ratio in P1 OA cells compared to the P0 OA
cells, an indicator for dedifferentiation of the cells. It is interest-
ing to note that in P1 OA chondrocytes, IL-1β expression
decreased further to levels found in healthy chondrocytes ex
vivo and in primary culture ACT chondrocytes (Figure 3).
In vivo cartilage formation
To investigate whether P0 OA chondrocytes might be
employed for the regeneration of cartilage defects by ACT, we
seeded such cells onto biphasic collagen scaffolds and
implanted them subcutaneously into immune deficient mice.
This scaffold consists of a very slowly degrading membrane
and a porous region (sponge) that is normally replaced by
cartilage-like tissue within eight weeks. After eight weeks of
implantation, no cartilage formation could be observed in the
empty control scaffolds (Figure 4a,b). Some scattered cells of
murine origin were present inside the scaffold (data not
shown). In scaffolds seeded with the lowest tested density of
chondrocytes (1 × 106 cells/cm2), cartilage-like tissue contain-
ing proteoglycans (Figure 4c) and type II collagen (Figure 4d)
was formed only in scaffolds seeded with cells from OA donor
1. In scaffolds seeded with cells from the other two OA donors
(Figure 4g,i) only isolated cells staining positive for type II col-
lagen could be observed, and there was insufficient cartilage
formation. However, when chondrocytes were seeded at a
higher density (3 × 106 cells/cm2), cartilage was generated by
cells from all three donors (Figure 4e,f,h,j), in levels similar to
those found in the scaffolds seeded with 1 × 106 healthy
chondrocytes/cm2 (Figure 4k; one sample of three healthy
donors). In these samples the spongy part of the scaffold was
completely replaced by hyaline-like cartilage, as indicated by
the presence of cells with a round, chondrocyte-like morphol-
ogy embedded in proteoglycan – (Figure 4e) and type II colla-
gen-rich tissue (Figure 4f,h,j). Hardly any type I collagen could
be detected in the newly formed cartilage (Figure 4l). The
absence of cell clustering (insert in Figure 4e), ALP activity
(Figure 4m) and of large, hypertrophic chondrocytes (insert in
Figure 1
Gene expression patterns of chondrocytes ex vivo Gene expression patterns of chondrocytes ex vivo. Chondrocytes were isolated from cartilage of healthy individuals (n = 6, white bars) or osteoar-
thritis (OA) patients (n = 20, black bars). The ex vivo gene expression of type I and II collagen (CI and CII, respectively), aggrecan (AGG), IL-1β and 
activin-like kinase (ALK)-1 was determined using qRT-PCR. The mRNA levels were normalized to GAPDH and amplified by a factor of 106. The col-
lagen type I to collagen type II mRNA ratio was calculated as a measure for the differentiation status of the chondrocytes. Statistically significant dif-
ferences (p < 0.05) are marked by asterisks (*).Arthritis Research & Therapy    Vol 9 No 3    Stoop et al.
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Figure 4e) suggest that these cells show no inclination to
become hypertrophic or to retain OA characteristics.
Gene expression of chondrocytes in scaffolds
To investigate the regenerative potential in OA chondrocytes
in comparison to ACT cells in more detail, cells from both
cohorts were expanded in primary culture, seeded onto colla-
gen scaffolds, and implanted subcutaneously into SCID mice
as described above. After eight weeks in situ, the scaffolds
were harvested to determine the gene expression patterns by
qRT-PCR. Samples derived from ACT patients showed no sig-
nificant differences in mRNA expression levels of any of the
genes investigated compared to cells from OA patients (Fig-
ure 5). Interestingly, the expression of IL-1β mRNA remained
below qRT-PCR detection levels in all the samples. Further-
more, only low levels of type X collagen mRNA expression
could be detected, suggesting that the implanted cells did not
become hypertrophic. We conclude from these data that
chondrocytes harvested from intact sites of articular cartilage
of OA patients are not significantly different with respect to the
factors investigated in this study and seem to retain at least
some regenerative potential.
Figure 2
Gene expression pattern of chondrocytes after primary culture (P0) Gene expression pattern of chondrocytes after primary culture (P0). Chondrocytes isolated from cartilage of patients undergoing autologous 
chondrocyte transplantation (ACT; n = 40, white bars) or osteoarthritis (OA) patients (n = 26; black bars) were expanded in primary culture for 10 to 
12 days and the gene expression of type I and II collagen (CI and CII, respectively), aggrecan (AGG), IL-1β and activin-like kinase (ALK)-1 was deter-
mined using qRT-PCR. The mRNA levels were normalized to GAPDH and amplified by a factor of 106. In comparison to cells ex vivo, the collagen 
type I to collagen type II mRNA ratio is increased, especially in ACT chondrocytes. Statistically significant differences (p < 0.05) are marked by aster-
isks (*).
Figure 3
Gene expression pattern of chondrocytes after first passage (P1) Gene expression pattern of chondrocytes after first passage (P1). Chondrocytes from cartilage of osteoarthritis (OA) patients (n = 18, black bars) 
were subcultured in a first passage and further expanded until they reached confluence after an additional 12 to 14 days. The gene expression pat-
terns were enumerated by qRT-PCR for type I and II collagen (CI and CII, respectively), aggrecan (AGG), IL-1β and activin-like kinase (ALK)-1 as 
indicated. The mRNA levels were normalized to GAPDH and amplified by a factor of 106. The ratio of type I to type II collagen mRNA levels continue 
to increase in P1 OA chondrocytes.Available online http://arthritis-research.com/content/9/3/R60
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Discussion
The advent of reliable cell culture techniques raised hopes that
tissue engineering might be able to cure any type of cartilage
damage, regardless of pathology, degeneration of tissue,
health status and age of patient [13]. In a recent study, regen-
eration of cartilaginous tissue was reported using chondro-
cytes from elderly donors [14] and ACT can be successful in
certain patients suffering from early stage arthritis [7]. This
encouraged us to investigate whether OA chondrocytes might
possibly be used for ACT.
Our data suggest that OA chondrocytes ex vivo are in a differ-
entiation state similar to that of healthy chondrocytes, as
shown by their low expression levels of ALK-1, similar expres-
sion levels of type I collagen, and high expression of type II col-
lagens and aggrecan mRNA. But OA chondrocytes ex vivo
contain significantly more IL-1β encoding mRNA. This could
cause major problems for their use in the ACT procedure,
since IL-1β is known to induce chondrocyte-mediated carti-
lage degradation [15,16] and to reduce type II collagen
expression [17]. Factors activating IL-1β expression in vivo –
as reflected by the highly elevated IL-1β mRNA amounts found
ex vivo – may contribute not only to the degradation of articular
cartilage during OA but at the same time induce a catabolic
situation in a transplant after ACT. Therefore, treatment of the
osteoarthritic joint prior to and directly after ACT by blocking
Figure 4
In vivo cartilage formation of osteoarthritic chondrocytes seeded on collagen scaffolds In vivo cartilage formation of osteoarthritic chondrocytes seeded on collagen scaffolds. Collagen scaffolds were seeded with human chondrocytes, 
implanted subcutaneously into SCID mice and harvested after eight weeks. (a,b) On empty scaffolds no cartilage formation occurred, as shown by 
the absence of dense Safranin O (a) or type II collagen (b) staining. (c,d) On scaffolds seeded with 1 × 106 osteoarthritic chondrocytes from oste-
oarthritis (OA) donor 1, moderate amounts of cartilage-like proteoglycan (c) and type II collagen (d) containing tissue could be detected. (g,i) How-
ever, hardly any type II collagen positive tissue was formed in scaffolds seeded with 1 × 106 chondrocytes from OA donors 2 (g) and 3 (i). (d,f,h,j) 
Seeding scaffolds at the higher density of 3 × 106 chondrocytes/cm2 resulted in the formation of type II collagen- and proteoglycan-rich cartilage by 
cells from all three donors in amounts comparable to those produced by (k) 1 × 106 healthy chondrocytes. (l,m) No type I collagen (l) or alkaline 
phosphatase activitiy (m) could be detected in these tissues. (c-f) OA donor 1, 78 years. (g,h,l) OA donor 2, 68 years. (i,j,m) OA donor 3, 50 years. 
(k) Healthy donor, 40 years. (a,c,e) Safranin O staining. (b,d,e-k) Type II collagen immunostaining. (m-o) Positive controls (OA cartilage, cartilage-
bone interface) for type I (n), type II (o) and alkaline phosphatase activity (insert in (m)). Bar = 250 μm.Arthritis Research & Therapy    Vol 9 No 3    Stoop et al.
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inflammatory processes or inhibiting catabolic factors should
be taken into consideration.
Upon primary culture of the OA chondrocytes, a strong reduc-
tion of IL-1β expression was accompanied by an increase in
type II collagen expression, even exceeding the levels found in
ACT chondrocytes cultured under the same conditions. It is
unclear whether this increase in type II collagen expression
results from a loss of an inhibitory effect of IL-1β or if this
reflects a general activation of gene expression described in
OA chondrocytes in vivo and ex vivo [18]. In addition to an
increase in type II collagen expression upon culture of the OA
cells, we also observed an increase in type I collagen and ALK-
1. In an earlier study [19], chondrocytes from OA patients in
first or second passage cultures did not differ significantly
from chondrocytes obtained from healthy donors with respect
to their type II and type I collagen expression patterns. In first
passage cells, the expression of transcription factors regulat-
ing collagen, including SOX-5, -6, and -9, appeared to be even
higher in OA chondrocytes. These findings are consistent with
our data, as a significantly lower ALK-1 expression and
collagen ratio were observed. However, an upregulation of
type X collagen expression has been reported in OA cells in
comparison with healthy chondrocytes [19]. This suggests
that OA chondrocytes in primary culture show fewer signs of
dedifferentiation but rather move towards a more hypertrophic
phenotype, which might limit their use for tissue engineering.
However, in our in vivo experiments, the cells did not show any
ALP activity, which is another marker for hypertrophic
chondrocytes [20]. This finding argues against a progression
of the cells towards a stage of hypertrophy. Further differences
in the expression of type X collagen between cells from ACT
and OA patients were not observed. Our results also show
that the production of high-quality ACT cells from
osteoarthritic cartilage does not necessarily require additional
manipulation of the cells such as alginate or agarose culture to
stabilize the chondrogenic phenotype in these cells [21,22].
The downregulation of IL-1β expression in OA chondrocytes
upon expansion implies that these cells are not irreversibly
changed. It is possible that the osteoarthritic tissue induced
the elevated IL-1β expression observed ex vivo. For example,
chondrocytes are known to upregulate the production of their
own pro-inflammatory cytokines, including IL-1β and tumor
necrosis factor-α, under the influence of proinflammatory
cytokines present in the synovial tissues of patients with early
OA [23,24], mechanical stress [25], and breakdown products
from the cartilage matrix [26,27]. At the same time, their
responsiveness to IL-1β is reduced [28], making these cells
less sensitive to autocrine IL-1β during in vitro expansion. This
may contribute to a normalization of IL-1β expression in vitro
as well. Interestingly, in cells seeded onto the type I collagen
scaffold, IL-1β mRNA was basically below detection levels
eight weeks after implantation. Therefore, to ensure the suc-
cess of ACT in OA joints, the control of articular environment
will be of the utmost importance. Control of inflammatory stim-
uli in the affected joint and the removal of any degenerated car-
tilage surrounding the primary defect probably will be as
important as the expansion of high quality autologous cells.
Using the SCID mouse model, we were able to show that OA
chondrocytes seeded onto collagen scaffolds were capable of
producing a hyaline cartilage in vivo. However, higher seeding
densities (3 × 106 cells/cm2) were needed than those cur-
Figure 5
Gene expression pattern of chondrocytes after in vivo inoculation in scaffolds Gene expression pattern of chondrocytes after in vivo inoculation in scaffolds. Chondrocytes from healthy donors (n = 3, white bars) and from oste-
oarthritis (OA) patients (n = 4, black bars) were expanded in primary culture, seeded onto scaffolds and incubated for four days in vitro, followed by 
implantation for eight weeks subcutaneously in SCID mice. Scaffolds were harvested and RNA was extracted from the cells to investigate the gene 
expression patterns by qRT-PCR for type I and II collagen (CI and CII, respectively), aggrecan (AGG), IL-1β and activin-like kinase (ALK)-1 as indi-
cated. The mRNA levels were normalized to GAPDH and amplified by a factor of 106. Cells from healthy donors expressed slightly more collagen, 
but no significant differences in gene expressions or differences in the type I to type II collagen ratio were observed between the ACT versus OA 
cells. ND, not detectable.Available online http://arthritis-research.com/content/9/3/R60
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rently used for ACT procedures (1 × 106 cells/cm2). Similar
results were found by Tallheden and colleagues [29] using a
scaffold based on hyaluronic acid. Although the reason for this
phenomenon is unclear, the higher inoculation density might
compensate for reduced mitotic activity, lower metabolic activ-
ity or elevated cell death of OA cells in the scaffolds [30,31].
However, it seems that patient age by itself is not a major fac-
tor for tissue formation using OA chondrocytes. The chondro-
cytes from one patient included in this study (78 years of age)
showed better in vivo tissue formation at lower inoculation
density than those of younger donors (68 and 50 years of
age). However, the influence of donor age on cartilage regen-
eration must be addressed in more detail in future studies.
Although our data suggest that chondrocytes from macro-
scopically intact cartilage of OA patients are of sufficient
quality themselves, a number of additional problems will need
to be solved before the ACT technique can become a viable
treatment option for osteoarthritic cartilage. For example, OA
defects are likely to be larger in size than most lesions currently
treated with ACT. This means that greater numbers of cells are
needed for the repair of cartilage damage in OA. We con-
firmed that extended expansion of OA chondrocytes beyond
the P0 stage was marked by a strong reduction in type II
collagen expression, upregulation of type I collagen expres-
sion and a slightly higher expression of ALK-1, showing ongo-
ing dedifferentiation in vitro. Since redifferentiation of
dedifferentiated, ALK-1high chondrocytes resulted in a fibrous
repair tissue [11], passaged OA chondrocytes are more likely
to regenerate a fibrous cartilage. Here, the harvest of addi-
tional donor cells from the respective joint might be a better
way of increasing the number of cells available for expansion
in order to cover the rather large defects seen in OA. However,
the additional damage to the joint resulting from the larger
number of biopsies will have to be balanced carefully against
the benefits of such an operation.
Furthermore, the challenge of preparing enough donor cells
from an osteoarthritic joint and additional problems, such as
joint stability, bone changes, and synovial inflammation, will
have to be addressed to optimize cartilage regeneration. One
subgroup of OA patients in which these problems might be
more solvable comprise patients with a unilateral, varus or val-
gus OA of the knee. In these patients, sufficient cartilage is
available to be used as donor material, the joint environment is
probably not as catabolic as in end-stage OA, and most impor-
tantly, it is possible to correct the cause of the OA by adjusting
the joint axis through osteotomy. Therefore, this group of
patients might benefit from treatment using the ACT method.
Conclusion
Our data suggest that chondrocytes from macroscopically
intact cartilage of OA patients can be expanded in vitro in a
quality suitable for scaffold-augmented ACT, although higher
initial cell densities were needed to ensure sufficient cartilage
formation. However, controlling the environment within these
joints will be of the utmost importance in ensuring the success
of ACT in OA patients. Hopefully, the development of novel tis-
sue engineering strategies, such as the anti-inflammatory or
growth-factor-releasing scaffolds currently under investigation
by numerous groups, will ensure the right environment to allow
the transplanted chondrocytes to restore the cartilage defect.
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